📰 Jay Luly News
Page 2 - Jay Luly News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jay Luly. Real-time updates on events, politics, business and more.
May 19, 2022
An antiviral that Enanta Pharmaceuticals is developing for respiratory syncytial virus infection failed to beat a placebo in its first Phase 2 test. But the biotech notes that these study participants weren’t very sick and may have recovered on their own, so it’s now pinning its hopes on ongoing studies in higher-risk groups, such as transplant patients.
February 9, 2022
ENTA earnings call for the period ending December 31, 2021.
November 23, 2021
ENTA earnings call for the period ending September 30, 2021.
November 23, 2021
ENTA earnings call for the period ending September 30, 2021.
October 12, 2021
The Merck pill, which could become the first oral antiviral COVID treatment, forces the SARS-CoV-2 coronavirus to mutate itself to death
March 2, 2021
03.01.21 -- Enanta Pharmaceuticals: From Failure To Formidable Cidara Therapeutics President and CEO Dr. Jeff Stein joins the Business of Biotech to discuss his career mission to battle microbial organisms and his companys development of a novel approach to producing immunotherapeutic antivirals that couple potent antivirals to a human antibody fragment. Listen now and subscribe so you never miss an episode. Featured Articles IBM and GE are some famous b...
February 22, 2021
A Behind The Scenes Look Into Enantas CEO, Jay Luly Source: Life Science Leader Follow Me On Twitter @RfwrightLSL Jay Luly, Ph.D., president and CEO, Enanta Pharmaceuticals “I grew up in Illinois,” shares Jay Luly, Ph.D., CEO of Enanta Pharmaceuticals. Luly is being interviewed for a future feature in Life Science Leader, and I started the conversation with a little ice breaker. Luly shares that somewhere along the way in high school, he figured out he wanted to study chemistry. Turns out ...
February 9, 2021
Operator Good afternoon, and welcome to Enanta Pharmaceuticals First Quarter 2021 Financial Results Conference Call. [Operator Instructions] There will be a question-and-answer session at the end of the prepared remarks. [Operator Instructions] I would now like to turn the conference over to Jennifer Viera, Investor Relations. Please go ahead. Jennifer Viera -- Investor Relations Thank you, operator, and thank you to everyone for joining us this afternoon. The news release with our fiscal firs...